Skip to content
RDL Network logo
Ibrutinib/Rituximab versus Placebo/Rituximab: A Randomized, Phase 3 Trial in Waldenström’s Macroglobulinemia (iNNOVATE) — M. Lia Palomba (2018) | RDL Network